Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D064420 | Drug-Related Side Effects and Adverse Reactions NIH | 0.71 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in elderly patients infected with COVID-19.
Description: Quantitative
Measure: To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen. Time: Three monthsDescription: Quantitative
Measure: To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen. Time: Three monthsDescription: Quantitative
Measure: To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19. Time: Three monthsDescription: Quantitative
Measure: To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score. Time: 3 monthsDescription: Qualitative
Measure: To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19. Time: 6 monthsDescription: Qualitative
Measure: To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used. Time: 1 year